17
total announcements
543213.BO · 15 min delayed
Rossari Biotech Ltd
Rossari Biotech Ltd has announced the transcript of its Q2 & H1 FY27 earnings conference call, which was held on October 19, 2026. The company reported a 19% year-on-year growth in revenue to Rs. 698 crore and a 21% year-on-year growth in EBITDA to Rs. 87 crore in Q2 FY27.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced the availability of the audio recording of its earnings conference call for Q2 and H1 FY27 on its website.
Rossari Biotech Ltd
Rossari Biotech Ltd reported its Q2 FY27 results, with highest-ever quarterly revenue of Rs. 697.6 crores, a 19.0% growth on y-o-y basis, and highest-ever quarterly EBITDA of Rs. 87.0 crores, a 20.9% growth on y-o-y basis. The company also announced the leasing of land for a greenfield manufacturing facility in the Kingdom of Saudi Arabia.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced its Q2 and H1 FY27 earnings, with a 19% YoY growth in Q2FY27 and a 23% YoY growth in H1FY27. The company has maintained its gross margin at ~32% and EBITDA margin at ~12.5% despite headwinds. The company has also announced the leasing of land to its subsidiary for a greenfield manufacturing facility in Saudi Arabia.
Rossari Biotech Ltd
Rossari Biotech Ltd has published the extract of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026, in accordance with Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026. The company's board of directors has approved the results, which were reviewed by the audit committee and subjected to 'limited review' by the statutory auditors. The company has also approved the leasing of land for setting up of greenfield manufacturing facilities in the Kingdom of Saudi Arabia.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, along with the approval for leasing of land for setting up of greenfield manufacturing facilities by Rossari International Limited, a wholly owned subsidiary.
Rossari Biotech Ltd
Rossari Biotech Ltd's Board of Directors approved unaudited financial results for the quarter and half year ended September 30, 2026, and also approved the leasing of land for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced an earnings conference call for investors and analysts to discuss Q2 & H1 FY27 financial results on October 19, 2026.
Rossari Biotech Ltd
Rossari Biotech Ltd has scheduled a Board Meeting on October 17, 2026, to consider and approve Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Rossari Biotech Ltd
Rossari Biotech Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of shares, mutilation, and cancellation of share certificates received for dematerialization during the quarter ended September 30, 2026.
Rossari Biotech Ltd
Rossari Biotech Ltd has informed the Exchange regarding the Trading Window Closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced an investor meet/conference/event on September 22, 2026, where the company will discuss its financial and other information available to the public.
Rossari Biotech Ltd
Rossari Biotech Ltd has informed about an investors and analysts meet/conference/events, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Rossari Biotech Ltd
Rossari Biotech Ltd has informed that it will not participate in the Nirmal Bang's Semi-Annual Investor Conference scheduled on August 10, 2026.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced an investor and analyst meet/conference on August 10, 2026, to discuss financial and other information available to the public or covered in the 'Earnings Presentation' submitted on July 19, 2026.
Rossari Biotech Ltd
Rossari Biotech Ltd has announced the transcript of its Q1 FY 27 earnings conference call, which was held on July 20, 2026. The company reported its highest ever quarterly revenue and EBITDA, with consolidated revenue growing 28% YoY. The management discussed its operational and financial performance, highlighting the company's diversified portfolio, extensive market research, and disciplined execution.